Bioventix PLC

LSE BVXP.L

Bioventix PLC Return on Capital Employed (ROCE) for the year ending June 30, 2024

Bioventix PLC Return on Capital Employed (ROCE) is NA for the year ending June 30, 2024. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Bioventix PLC Return on Capital Employed (ROCE) for the year ending June 30, 2022 was 77.37%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

LSE: BVXP.L

Bioventix PLC

CEO	Mr. Peter John Harrison MA
IPO Date	April 29, 2014
Location	United Kingdom
Headquarters	27–28 Eastcastle Street
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

Key trends

Past 5 years